Zheng W, et al. - In this prospective, multi-center, open-label clinical trial, researchers investigated in adult Chinese patients whether it is safe and efficacious to administer polyethylene glycol-conjugated asparaginase (PEG-ASP) combined with cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisolone (CHOP) (PEG-L-CHOP) to treat natural killer (NK)/T-cell lymphoma (NKTCL). They administered six cycles of PEG-L-CHOP regimen, with radiotherapy scheduled after 2–4 cycles based on the stage and primary anatomic site, in patients with newly diagnosed adult NKTCL and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. The estimated overall survival at 1, 2, 3-year were 100%, 90.61% and 80.54%, respectively. Bone marrow suppression, reduction of fibrinogen level, liver dysfunction, and digestive tract toxicities were documented as the major adverse effects. Overall, PEG-L-CHOP chemotherapy in combination radiotherapy was identified to be a safe and durably effective treatment for adult extranodal NK/T-cell lymphoma with less allergic reactions.